Back grey_arrow_rt.gif
 
 
Isentress Label Updated with 96 weeks Data
 
 
  On June 29, 2010, the Isentress (raltegravir potassium) tablet label was updated with the Week 96 safety and efficacy results in treatment-naïve and treatment-experienced patients.
 
In the treatment-naïve trial 021, the proportion of subjects with HIV RNA < 50 copies/mL was 82% for the Isentress 400 mg twice daily regimen compared to 78% for the Efavirenz arm. The treatment difference and 95% CI was 3.8% (-2.8%, 10.4%).
 
In the treatment-experienced pooled analysis of trials 018 and 019, the proportion of subjects with HIV RNA < 50 copies/mL was 55% for the Isentress 400 mg twice daily + optimized background regimen compared to 27% for the optimized background regimen arm.
 
Section 6 of the label was updated to include the Week 96 safety results. The complete revised label will be posted soon to the FDA website at Drugs@FDA. Be sure to check for 6/29/2010 update.
 
Richard Klein Office of Special Health Issues Food and Drug Administration Kimberly Struble Division of Antiviral Drug Products Food and Drug Administration
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org